Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343642 · ClinicalTrials.gov registry record · Phase 1
Dietary Treatment of Crohn's Disease
A Phase 1 study of Crohn's Disease and Inflammatory Bowel Disease, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 2
- Study locations
NCT00343642 is a Phase 1 study of Crohn's Disease and Inflammatory Bowel Disease that has completed, run by Rush University Medical Center. The registered enrollment target is 73 participants, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00343642, a Phase 1 study of Crohn's Disease and Inflammatory Bowel Disease, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 2
- Study locations
Study Summary
Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.
Conditions Studied
Interventions
- DRUG Active fructo-oligosaccharide
- DRUG Placebo fructo-oligosaccharide
- DIETARY_SUPPLEMENT Diet
Study Locations (2)
Georgia
- Gastroenterology Associates of Central Georgia - Macon
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343642
The ClinicalTrials.gov registry entry for NCT00343642 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (97% lower). The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Crohn's Disease appearing as the primary indexed condition, and to 3 interventions - of which Active fructo-oligosaccharide is the first listed.
NCT00343642 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT00343642 about?
NCT00343642 is a clinical study titled "Dietary Treatment of Crohn's Disease". Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.
What is the current status of trial NCT00343642?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2006-09. Estimated completion is 2012-10.
What conditions does trial NCT00343642 study?
This clinical trial studies the following conditions: Crohn's Disease, Inflammatory Bowel Disease.
What interventions are being tested in trial NCT00343642?
The interventions under investigation include: Active fructo-oligosaccharide (DRUG), Placebo fructo-oligosaccharide (DRUG), Diet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00343642?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00343642 being conducted?
This trial has 2 study locations across Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Stem Cell Transplantation for Crohn's Disease
RECRUITING · Phase 1
-
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
RECRUITING · Phase 1
-
Beta-Hydroxybutyrate Feasibility Treating IBD
RECRUITING · Phase 1
-
Treatment of Moderate to Severe Refractory Crohn's Disease
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
ACTIVE NOT RECRUITING · Phase 1
-
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.